medigraphic.com
ISSN 1025-0255 (Electronic)

2015, Number 4

<< Back Next >>

AMC 2015; 19 (4)

Evolution of complex lesions in the diabetic foot using Heberprot-P®

Silva PM, González MIA, Valenciano GY, González CM

Language: Spanish
References: 21
Page: 357-365
PDF size: 596.81 Kb.


ABSTRACT

Background: diabetic foot is one of the most alarming chronic complications of diabetes mellitus because of the risk of amputations of the inferior limbs and the psycho-social damage that entails. There are areas prone to unfavourable lesions like the calcaneus region and the plantar area.
Objective: to evaluate the evolution of complex lesions in diabetic foot with the use of Heberprot-P®.
Methods: a descriptive, longitudinal, retrospective study was made to the patients admitted in the "Manuel Ascunce Domenech" Provincial Hospital with the diagnosis of diabetic foot between June 2013 and April 2014. The patients presented complex lesions. The universe was composed of 48 patients. The non-probabilistic sample included 36 patients who matched the established inclusion and exclusion criteria. The information obtained was processed by means of the statistical program SPSS-11.5 for Windows and the descriptive statistics with distribution of frequencies and percents. The results of the study were exposed in tables.
Results: it was found that female was the most affected sex with a higher incidence in the age group 56-65. The etiological diagnosis of diabetic foot was neuroinfectious. The most affected inferior limb was the right foot. Wagner classification of level 3 included most of the cases. The research had a successful outcome with 33 closed cases.
Conclusions: the purpose of handling with diabetic foot ulcers is to prevent amputation and keeping a good quality of life. Heberprot-P® is a product that modifies the amputation criteria and is a valuable option for the patient and the doctor.


REFERENCES

  1. Li Y, Burrows NR, Gregg EW, Albright A, Geiss LS. Declining rates of hospitalization for nontraumatic lower-extremity amputa-tion in the diabetic population aged 40 years or older: U.S., 1988–2008. Diabetes Care. 2012 Feb;35(2):273–7.

  2. Campos Acosta Y, Melgarejo Rivero B, Jai-me Cabrera Z, Pol Marrón N, Vargas Machi-rán E, Pérez Leonard D, et al. Comporta-miento de la función renal en pacientes con úlcera de pie diabético tratados con Heberprot-P®. Rev cuba angiol y cir vasc. Ene-Jun 2014;15(1):13-21.

  3. González Acosta S, Calaña González-Posada B, Marrero Rodríguez I, López Fer-nández R. Evolución clínica del tratamiento en el pie diabético con Heberprot-P o con el método convencional. Rev cuba angiol y cir vasc. 2011;11(2):8-17.

  4. Fernández Montequín J, Herrera Martínez LS, Negrín Martínez S, Berlan Acosta J, Ló-pez Mola E, Valdés Pavón RA, et al. Manual de promotores Heberprot p. Una herra-mienta imprescindible para los heberpro-pistas. La Habana: Elfos Scientiae; 2011.

  5. Raíces Pérez MR. II edición del congreso internacional sobre la Atención integral al paciente con úlceras del pie diabético con el uso de Hebeprot-P 2012: Puertas sanas abiertas a la edición de 2014. Biotecnol apl. Ene-Mar 2013;30(1):56-73.

  6. Berlanga Acosta J, Fernández Montequín JI, López Mola E, López Saura PA, del Río A, Valenzuela C, et al. Heberprot-P: A novel product for treating advanced diabetic foot ulcer. MEDICC Review [Internet]. 2013 Jan [cited 2013 Feb 12];15(1):[about 9 p.]. Available from: http://www.medicc.org/mediccreview/index.php?issue=23&id=287&a=va

  7. Fernández Montequín JI. Una victoria de la Medicina Cubana en Angiología y Cirugía Vascular. Rev cuba angiol cir vasc. Ene-Jun 2013;14(1):45-53.

  8. Berlanga Acosta J. Heberprot-P: experi-mental background and pharmacological bases. Biotecnol apl [Internet]. 2010 Jun [cited 2012 Mar 13];27(2):[about 6 p.]. Available from: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1027-28522010000200002&lng=es

  9. Martínez Durán P, Aguilera Elena M. Im-pacto del uso del Heberprot-P en el munici-pio Cacocum en 2012. CCM. Abr-Jun 2013;17(2):21-35.

  10. Machado Novell K, Leyva Mora AM, Alonso Salceda K, Hernández Pérez JR, Labarta Rodríguez DM. Eficacia del tratamiento del Heberprot–P en un paciente con pie diabé-tico neuroinfeccioso. CCM. Jul-Sep 2013;17(3):32-9.

  11. CDC [Internet]. Atlanta (US): Center for Disease Control and Prevention (US); 2012. 2011 National Diabetes Fact Sheet; [updated 2012 Jan; cited 2012 Sep]; [2.7 MB]. Available from: www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf

  12. Fernández-Montequín JI, Santiesteban Ll. Can Heberprot-P change the surgical con-cepts on treating diabetic foot? Biotecnol apl [Internet]. 2010 Abr-Jun [cited 2013 Mar 13];27(2):[about 5 p.]. Available from: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1027-28522010000200011&lng=es

  13. Rodríguez Gurri CD. Caracterización de los pacientes con pie diabético tratados con Heberprot-P® en el Hospital Militar de Hol-guín. Rev cuba angiol y cir vasc. Ene-Jun 2014;15(1):24-31.

  14. Hernández Rivero MJ, Llanes Barrios JA, Acosta Lapera DS. Heberprot-P, una tera-pia eficaz en la prevención de la ampu-tación en el pie diabético. Rev cuba angiol y cir vasc [Internet]. Ene-Dic 2009 [citado 13 Mar 2013];10(1):[aprox. 8 p.]. Disponi-ble en: http://www.bvs.sld.cu/revistas/ang/vol10_1_09/angsu109.htm

  15. Álvarez Crespo A, Alonso Carbonell L, Yera Alós I, García Milián AJ. Evolución clínica de pacientes con úlcera del pie diabético tratados con Heberprot-P®. Arch méd Cama-güey. Sep-Oct 2013;17(5):21-34.

  16. Escobar Amarales Y, Torres Romo UR, Es-calante Padrón O, Fernández Franch N, Iba-rra Viena V, Miranda Rodríguez E. El He-berprot-P® en el tratamiento de úlceras del pie diabético. Arch méd Camagüey. May-Jun 2014;18(3):35-46.

  17. Morales Florat JL, Vázquez Torres M, Gutié-rrez Postigo Y. Experiencia del programa de atención integral a pacientes con pie diabé-tico. Rev Española de Inv Quir [Internet]. 2011 [citado 13 Mar 2012];XIV(4):[aprox. 5 p.]. Disponible en: http://dialnet.unirioja.es/servlet/articulo?codigo=3801414

  18. Escalante Padrón O, Álvarez Escalante G, Manchola Padrón E, Álvarez HidalgoR. Impacto social de una Tecnociencia: He-berprot-P. Hum méd. Ene-Abr 2014;14(1):12-23.

  19. Fernández Montequin JI, Mena G, San-tiesteban Ll. Treatment and recovery of Wagner 5 diabetic foot with Heberprot-P. Biotecnol apl [Internet].

  20. 2010 Abr-Jun [cited 2013 Mar 13];27(2):[about 4 p.]. Available from: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1027-28522010000200005&lng=es

  21. Franco Pérez N, Valdés Pérez C, Llanes Ba-rrios JA, Reynaldo Concepción D, Pérez Leo-nard D. Las amputaciones de dedos abiertas y cerradas: su evolución en el pie diabético. Rev cuba angiol cir vasc. Ene-Dic 2010;11(1):12-23.




2020     |     www.medigraphic.com